Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Sunn aldring hos personer med epilepsi-program (HAP-E)

10. juni 2026 oppdatert av: Anny Reyes

Sunn aldring hos mennesker med epilepsi-program (HAP-E): Å lukke gapet i epilepsiomsorgen

Målet med denne kliniske studien er å utvikle og teste et pedagogisk program om demens hos eldre voksne som lever med epilepsi. Hovedspørsmålene den tar sikte på å besvare er:

  1. Kan det å gi opplæring om sunn aldring, kronisk sykdomshåndtering, demens og modifiserbare livsstilsdemensrisikofaktorer forbedre demenskunnskap og helsekompetanse blant eldre voksne med epilepsi?
  2. Kan aldringsrelatert utdanning og ressurser forbedre livskvaliteten blant eldre voksne med epilepsi?

Deltakerne vil:

  • Fullfør et 12-ukers gruppeutdanningsprogram.
  • Fullfør før- og etterprogramevaluering.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

380

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Ohio
      • Cleveland, Ohio, Forente stater, 44195
        • Rekruttering
        • Cleveland Clinic
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Ja

Beskrivelse

Inklusjonskriterier:

  • Nåværende diagnose av epilepsi satt av en nevrolog, epileptolog eller internist/familielege
  • Ferdigheter i engelsk

Ekskluderingskriterier:

  • Demens

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: Part 1a: Patient Survey
Patients with receive an online survey to identify barriers in accessing geriatric care, target educational topics, and concerns about aging. Additionally, they will be surveyed on unmet needs in their care, availability of healthcare information and resources related to aging and dementia, and elements of the program most important to them.
Patients with receive an online survey to identify barriers in accessing geriatric care, target educational topics, and concerns about aging. Additionally, they will be surveyed on unmet needs in their care, availability of healthcare information and resources related to aging and dementia, and elements of the program most important to them.
Annen: Part 1b: Provider Survey
Providers will receive an online survey to identify barriers in accessing geriatric care, target educational topics, and concerns about aging.
Providers will receive an online survey to identify barriers in accessing geriatric care, target educational topics, and concerns about aging.
Eksperimentell: Part 3: Intervention
Participants randomized to this group will receive a 12-week group educational program (either virtual or in-person based on patient preference) providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors.
Dette er et 12-ukers gruppeutdanningsprogram som gir opplæring om sunn aldring, behandling av kroniske sykdommer, demens og modifiserbare risikofaktorer for livsstilsdemens.
Ingen inngripen: Part 3: Control
Participants randomized to this group will receive standard care during their participation

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Dementia Knowledge
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
Dementia Knowledge Assessment Tool was designed to measure change in knowledge of dementia including dementia and its progress, support, and care. It contains 21 true/false items (higher score indicates greater dementia knowledge).
Baseline (Week 0) and post-intervention (Month 3)
Acceptability of Study Program
Tidsramme: Post-intervention (Month 3)
Defined by participation rate of 80% or greater in intervention (higher number indicates greater acceptability of the program)
Post-intervention (Month 3)
Program Satisfaction
Tidsramme: Post-intervention (Month 3)
As assessed by Client Satisfaction Questionnaire (Min-Max 8-32, higher number is greater satisfaction)
Post-intervention (Month 3)
Epilepsy Self-Management
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
Use of epilepsy self-management practices will be assessed with the Epilepsy Self-Management Scale (Min-Max 38-190, higher score means more frequent use of self-management strategies).
Baseline (Week 0) and post-intervention (Month 3)
Attitudes about Aging
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
As measured by the Attitudes about Aging questionnaire (3 subscales with Min-Max 8-40; for two subscales, higher score mean more positive attitude; and for the third subscale, higher score means more negative attitude)
Baseline (Week 0) and post-intervention (Month 3)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Health literacy
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
Assessment of participants' health literacy will be done by the Short Assessment of Health Literacy-English (Min-Max 0-18, lower number indicates lower health literacy)
Baseline (Week 0) and post-intervention (Month 3)
Participant's Quality of life
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
As assessed by Quality of life in Epilepsy-31 (raw scores are converted to T-scores and higher T-scores indicate better quality of life) and the Quality of Life in Neurological Disorders (Likert scale format ranging from "Never" to "Always").
Baseline (Week 0) and post-intervention (Month 3)
Participant's confidence in managing different aspects of health
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
As measured by the Chronic Disease Self-Efficacy Scale (contains 10 subscales where the score for each scale is the mean of the items, higher numbers indicate higher self-efficacy)
Baseline (Week 0) and post-intervention (Month 3)
Participant's Mood
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
As measured by Geriatric Anxiety Inventory (Min-Max 0-20, higher scores indicate greater number of reported anxiety symptoms) and Geriatric Depression Scale (Min-Max 0-15, higher score indicates more depression symptoms)
Baseline (Week 0) and post-intervention (Month 3)
Cognitive Function
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
As measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (raw scores are converted to scaled scores to adjust for age, higher scores indicate better performance), the Trail Making Test (measured by total time of completion with higher scores indicating poorer performance), the Test of Practical Judgment (raw scores converted to z-scores based on normative sample, lower z-scores indicating loss of everyday judgment abilities), the Everyday Cognition (scored by on four-point scale, higher total score indicates greater subjective decline in cognitive function), and the Functional Assessment Questionnaire (Min-Max 0-30, higher scores indicate greater impairment in activities of daily living)
Baseline (Week 0) and post-intervention (Month 3)
Sleep quality
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
Measured with the Pittsburgh Sleep Quality Index (PSQI). The PSQI measures the quality and patterns of sleep in older adults. A global score is generated ranging from 0 to 21, with total score higher than 5 indicating "poor" sleeper.
Baseline (Week 0) and post-intervention (Month 3)
Health-promoting behaviors
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
Health promoting behaviors will be measured with the Health-Promoting Lifestyle Profile II (HPLP-II). The HPLP-II is a 52-item behavior rating scale employs a 4-point response format to measure the frequency of self-reported health-promoting behaviors in the domains of health responsibility, physical activity, nutrition, spiritual growth, interpersonal relations and stress management. A total score is generating by averaging across all 52 items with higher scores indicating higher number of health-promoting behaviors. Six subscales are also generated by averaging across the items for each subscale.
Baseline (Week 0) and post-intervention (Month 3)
Cognitive screening
Tidsramme: Baseline
The Telephone Montreal Cognitive Assessment (T-MoCA) will be used as screening tool of cognition; the T-MoCA is a modified version of the MoCA-30 that can be administered by phone and measures global cognitive functioning. Raw scores range from 0 to 22 with higher scores indicating better performance.
Baseline
Alcohol and smoking history
Tidsramme: Baseline (Week 0) and post-intervention (Month 3)
Information on alcohol use including frequency and types of alcohol consumed and smoking status, amount of smoking, and age at smoking cessation will also be collected.
Baseline (Week 0) and post-intervention (Month 3)

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Participant clinical and demographic characteristics
Tidsramme: Baseline
Participant age, gender, race, ethnicity, marital status, education level, primary language, and working status/profession will be collected of all participants. Epilepsy clinical history including age of onset, medications, seizure frequency, history and type of surgery, injury related to and seizures. Other medical and psychiatric history including hypertension, diabetes, hyperlipidemia, mood disorders (depression, anxiety), and family history of dementia.
Baseline

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Anny Reyes, PhD, The Cleveland Clinic

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. mars 2026

Primær fullføring (Antatt)

31. juli 2030

Studiet fullført (Antatt)

1. august 2030

Datoer for studieregistrering

Først innsendt

18. september 2023

Først innsendt som oppfylte QC-kriteriene

18. september 2023

Først lagt ut (Faktiske)

25. september 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. juni 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • IRB 25-598
  • 1K23NS138682-01A1 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data to be shared will include clinical and demographic information, quantitative survey responses, self-report and cognitive assessment data, and summaries of focus group discussions with stakeholder recommendations, along with associated documentation such as codebooks and analytic materials to support interpretation and reuse.

IPD-delingstidsramme

Beginning within the first year after study completion (August 2030) with no end date.

Tilgangskriterier for IPD-deling

IPD and supporting information will be accessible to the general public, who will be able to obtain de-identified participant data and relevant documentation through open, unrestricted access on a public data-sharing platform.

IPD-deling Støtteinformasjonstype

  • SEVJE
  • ICF
  • ANALYTIC_CODE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere